Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Scope & Guideline

Leading the Charge Against Mycobacterial Infections

Introduction

Explore the comprehensive scope of Journal of Clinical Tuberculosis and Other Mycobacterial Diseases through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Journal of Clinical Tuberculosis and Other Mycobacterial Diseases in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2405-5794
PublisherELSEVIER
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2015 to 2024
AbbreviationJ CLIN TUBER OTH MYC / J. Clin. Tuberc. Other Mycobacterial Dis.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The Journal of Clinical Tuberculosis and Other Mycobacterial Diseases focuses on advancing the understanding, diagnosis, treatment, and epidemiology of tuberculosis and other mycobacterial infections. It serves as a platform for disseminating research that addresses critical challenges in the management of these diseases.
  1. Epidemiology and Public Health:
    The journal emphasizes research on the epidemiology of tuberculosis and mycobacterial diseases, examining prevalence, risk factors, and public health implications across different populations and regions.
  2. Clinical Management and Treatment:
    It covers studies related to the clinical management of tuberculosis and other mycobacterial infections, including treatment regimens, drug resistance patterns, and the efficacy of novel therapies.
  3. Diagnostic Innovations:
    The journal highlights advancements in diagnostic methods for tuberculosis and mycobacterial diseases, focusing on novel technologies and methodologies that improve detection and monitoring.
  4. Co-Morbidities and Complications:
    Research addressing the interactions between tuberculosis and other health conditions, such as HIV, diabetes, and malnutrition, is a core focus, providing insights into managing patients with multiple health issues.
  5. Non-Tuberculous Mycobacterial Diseases:
    The journal includes studies on non-tuberculous mycobacterial infections, expanding the scope of research to encompass a broader range of mycobacterial diseases beyond tuberculosis.
Recent publications indicate a dynamic shift towards innovative themes and urgent public health challenges within the field of tuberculosis and mycobacterial diseases. These emerging trends reflect current global health priorities and research needs.
  1. Drug-Resistant Tuberculosis:
    The prevalence and management of multidrug-resistant tuberculosis (MDR-TB) has become a prominent focus, as researchers seek to address the growing challenge of drug resistance in various populations.
  2. Integrated Care Approaches:
    There is a rising interest in integrated care models that combine tuberculosis management with other health services, particularly in addressing co-morbid conditions such as HIV and diabetes.
  3. Digital Health Innovations:
    The use of digital health technologies, including telemedicine and mobile health applications, is gaining traction for improving tuberculosis management and adherence to treatment protocols.
  4. Socioeconomic and Behavioral Factors:
    Research examining the social determinants of health, including socioeconomic factors and patient behaviors, is increasingly featured, highlighting their impact on tuberculosis outcomes.
  5. Global Health Initiatives:
    Emerging themes include research related to global health initiatives, such as strategies to enhance tuberculosis screening, prevention, and treatment in low-resource settings.

Declining or Waning

While the journal maintains a broad focus, certain themes have shown a decline in publication frequency or relevance over recent years. This may reflect shifts in research priorities or emerging challenges in the field.
  1. Traditional Treatment Approaches:
    There is a noticeable decline in publications focusing on traditional treatment regimens for tuberculosis, as research increasingly shifts towards novel therapies and drug-resistant strains.
  2. Basic Laboratory Research:
    Research centered around basic laboratory studies of Mycobacterium species has decreased, possibly due to the growing emphasis on clinical and translational research that directly impacts patient care.
  3. Single-Country Studies:
    The prevalence of single-country studies has waned, with a trend towards multi-country studies or global perspectives that provide a more comprehensive understanding of tuberculosis and mycobacterial diseases.
  4. Historical Epidemiological Data:
    There seems to be a reduction in studies focusing on historical epidemiological data without addressing current implications, as the journal increasingly prioritizes contemporary research that informs current practices.

Similar Journals

Expert Review of Anti-Infective Therapy

Advancing the Fight Against Infectious Diseases
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-7210Frequency: 12 issues/year

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Tuberculosis and Respiratory Diseases

Exploring the frontiers of respiratory disease management.
Publisher: THE KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASESISSN: 1738-3536Frequency: 4 issues/year

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

MIKROBIYOLOJI BULTENI

Exploring Innovations in Infectious Disease Research
Publisher: ANKARA MICROBIOLOGY SOCISSN: 0374-9096Frequency: 4 issues/year

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

International Journal of Mycobacteriology

Leading the charge in mycobacteriology research and treatment.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2212-5531Frequency: 4 issues/year

International Journal of Mycobacteriology is a peer-reviewed, open-access journal published by Wolters Kluwer Medknow Publications that specializes in the field of infectious diseases with a particular emphasis on mycobacterial research. Since its inception in 2012, this journal has emerged as a vital resource for researchers, healthcare professionals, and students aimed at advancing understanding and treatment of mycobacterial infections, including tuberculosis. With the journal being indexed in Scopus and holding a Q3 ranking in both Infectious Diseases and Microbiology (medical) for 2023, it reflects a substantial contribution to scholarly discourse in these domains, despite its current ranking positioning. Authors and readers benefit from the open access model, ensuring widespread dissemination of research findings and fostering collaboration across the global health community. Located in Mumbai, India, the journal continues to thrive with a commitment to quality research and innovation, welcoming contributions that further the exploration of mycobacteriology throughout the converged years from 2012 to 2024.

Hepatitis Monthly

Exploring the frontiers of viral hepatitis understanding.
Publisher: BRIEFLANDISSN: 1735-143XFrequency: 12 issues/year

Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.

INFECTION

Leading the Charge in Microbial Research
Publisher: SPRINGER HEIDELBERGISSN: 0300-8126Frequency: 6 issues/year

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

JOURNAL OF CLINICAL MICROBIOLOGY

Navigating the Complexities of Microbial Pathogens
Publisher: AMER SOC MICROBIOLOGYISSN: 0095-1137Frequency: 12 issues/year

JOURNAL OF CLINICAL MICROBIOLOGY, published by the American Society for Microbiology, stands as a premier resource for researchers and professionals in the field of medical microbiology. With an illustrious history dating back to 1975, this journal has consistently provided high-impact research, reflecting its status in the Q1 category among microbiology (medical) journals, and an impressive Scopus rank of 14 out of 140, placing it in the 90th percentile. The journal's commitment to unveiling foundational and innovative studies greatly contributes to understanding human health challenges posed by microbial pathogens. Researchers can expect rigorous peer-reviewed articles that cover a spectrum of topics, from diagnostic methods to clinical epidemiology, fostering a deeper understanding of microbiology's role in healthcare. While this journal does not offer open access options, its substantial impact factor underscores its relevance in shaping the conversation in clinical microbiology. The JOURNAL OF CLINICAL MICROBIOLOGY is indispensable for anyone dedicated to advancing their knowledge and practical skills in microbiology.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Fostering innovation in the understanding of infectious agents.
Publisher: EDICIONES DOYMA S AISSN: 0213-005XFrequency: 10 issues/year

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA is a prominent journal dedicated to the fields of infectious diseases and clinical microbiology, published by EDICIONES DOYMA S A in Spain. With an ISSN of 0213-005X and an e-ISSN of 1578-1852, the journal has been a cornerstone of research and scholarly communication since its inception in 1989. As of 2023, it holds a Q3 category ranking in Infectious Diseases, highlighting its significance in the field, alongside a Q4 ranking in the related area of Microbiology. Although the journal is not open access, it remains an essential resource for professionals, researchers, and students aiming to stay informed on advancements and studies that impact clinical practices in infectious diseases. With Scopus ranks indicating a percentile ranking in the 20th to 34th range across various sub-disciplines, ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA continually contributes to the dialogue and development of science, fostering a deeper understanding of complex microbial interactions and disease mechanisms.

Infection and Drug Resistance

Championing open access for groundbreaking research in infection control.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6973Frequency: 1 issue/year

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Revista Chilena de Infectologia

Advancing knowledge in infectious diseases and public health.
Publisher: SOC CHILENA INFECTOLOGIAISSN: 0716-1018Frequency: 6 issues/year

Revista Chilena de Infectologia is an esteemed academic journal dedicated to the field of infectious diseases and public health. Published by the SOC CHILENA INFECTOLOGIA, this journal has been pivotal in disseminating crucial research findings since its inception in 2000. While operating under ISSN 0716-1018 and E-ISSN 0717-6341, it aims to contribute to the understanding of both local and global health issues, particularly within the context of Chile. Currently, it holds a Q4 ranking in both the Infectious Diseases and Public Health, Environmental and Occupational Health categories as of 2023, reflecting its unique position among emerging voices in the field. The journal aspires to foster collaboration among researchers, professionals, and students by offering a platform for innovative studies and discussions that address pressing health challenges. Although it is not an Open Access journal, access options through institutional subscriptions are encouraged for a comprehensive review of its significant contributions to infectious disease research.